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Background: Oral glucocorticoids (steroids) are the mainstay of treatment for systemic lupus erythematosus (SLE),
but their use is often associated with short- and long-term side effects. Following a literature review and
discussions with patients with SLE, clinicians, and payers, a need was identified for a comprehensive SLE-specific
tool that can be used to evaluate the side effects and benefits of steroids over time from a patient perspective. The
objective of this study was to develop a patient-reported outcome (PRO) measure to assess general impact
(baseline burden), benefits, side effects, and impacts associated with the use of oral steroids in patients with SLE.
Methods: A qualitative research protocol was developed in which adults with SLE currently receiving or who had
received steroids in the past year were recruited from six US rheumatology practices to participate in concept
elicitation (CE) interviews. The SLE Steroid Questionnaire (SSQ) was developed based on CE interview results and
clinical input. Cognitive debriefing interviews with a second group of patients with SLE evaluated the content,
clarity, and relevance of the items. The SSQ was refined using patient feedback, clinician review, and a translatability
assessment. The protocol received central independent review board approval.
Results: Thirty-three patients (52% moderate disease severity; 58% currently receiving steroids, mean dose 8.7 mg/day)
completed CE interviews. Patients reported benefits, side effects, and impacts from steroids. The refined SSQ contains
50 items assessing steroid dose/duration (4 items), general impact (baseline burden; 19 items), benefits (7 items),
work/productivity (3 items), side effects (10 items), emotions (6 items), and overall satisfaction (1 item).
Conclusion: The SSQ is a unique PRO, developed using robust scientific methodology in accordance with the
Food and Drug Administration PRO Guidance. It was designed to comprehensively assess the patient experience with
steroid therapy and better understand the benefits and burden of steroids for patients with SLE.
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Oral glucocorticoids (steroids) are the mainstay of
treatment for several auto-immune and inflammatory
disorders, including systemic lupus erythematosus
(SLE). While providing significant clinical benefits to
patients, their use is associated with both short- and
long-term side effects, which increase with dose and
duration of use [1–5]. Long-term steroid use can lead
to life-limiting adverse events (AEs) and have a negative
impact on quality of life (QoL) [6].
Perspectives on the risks and benefits of steroids may
vary between patients, physicians, and policymakers
(“payers”). In particular, the patient perspective or
experience is not necessarily well understood or docu-
mented. A recent study found that patients with SLE
thought their physician needed a better understanding
of the psychosocial difficulties and pressures they face
and that these should be considered when making treat-
ment decisions [7]. The impact of steroid use and the
value of steroid-sparing has only been partially explored
within clinical trials. Clinical trials provide a controlled
environment in which to explore short-term benefits of
steroid sparing; AEs are collected, but the interplay
between efficacy, safety, and QoL has only been partially
resolved, and the moderating effect of these negative
outcomes on the holistic benefit to patients is often not
captured. At a Scientific Advisory Board meeting (‘The
impact of corticosteroids in SLE’; March 2014; sponsored
by GSK) physicians and payers concluded that whilst
many physicians see the importance of sparing/replacing
steroids, others may view them as an effective treatment
with manageable side effects. Payers may also be reluctant
to pay a premium for new therapies that replace or reduce
the dose of steroids in the absence of evidence to demon-
strate what steroid-sparing will deliver in terms of redu-
cing side effects, QoL benefits, and/or cost reductions
(meeting minutes on file).
In the treatment of SLE, there is clinical consensus that
the dose of steroids should be kept as low as possible or
eliminated [7, 8]. Understanding the risks and benefits of
steroid treatment, dependent upon disease, dose and lon-
gevity of use, would inform the debate about their value
and how they should be best utilized in treatment. Steroid
use needs to be appropriately managed by clinicians and
patients, and should include careful consideration of the
appropriateness of other available treatment options, the
impact of steroid induced AEs, and any follow-on health-
care costs. Furthermore, assessing the impact and benefit
of primary SLE treatments can be challenging unless the
effects of steroids are fully taken into account, due to the
potentially confounding effect of steroid therapy on
efficacy measures. Only when steroid prescribing is
informed by robust evidence, can the true value of sparing
steroids in long-term clinical practice be estimated.A literature and background review, carried out to
identify potential patient-reported outcome (PRO) tools
that assess the impact of steroids in patients with SLE,
failed to identify any appropriate, fit for purpose
measures. The search identified 113 citations from Clini-
calTrials.gov, PubMed, EMBASE, PROQOLID, and con-
ference abstracts. Only one tool was identified; it was
initially developed for use in patients who receive oral
steroids for the treatment of immune thrombocytopenic
purpura, and measures the frequency and level of
distress of 33 symptoms patients experienced during the
past 4 weeks [9]. It was deemed unsuitable due to its
focus on symptoms alone, and the recall period was too
long to address frequent fluctuations associated with
symptoms and steroid use in patients with SLE. Due to
frequent changes in SLE symptoms and response to
treatment, it is essential that a PRO measure is sensitive
to change over time [10].
Following the background review and discussions
with patients, clinicians, and payers, a need was iden-
tified for a comprehensive SLE-specific tool that can
be used to evaluate the side effects and benefits of
steroids over time.
In 2009, the Food and Drug Administration (FDA)
released a guidance document for the development of
PROs that could be used in medical product develop-
ment. The guidance recommends that an iterative devel-
opment process should be undertaken to develop a
content-valid measure with adequate measurement
properties [11]. The guidelines recommend obtaining
significant patient input to identify important concepts,
developing a conceptual framework, and conducting
cognitive interviewing of patients to assess the content,
clarity, and relevance of the draft PRO. It is important
that features such as the recall period, response options,
question format, and translatability are considered.
The objective of this study was to develop a PRO
measure, the SLE Steroid Questionnaire (SSQ), which
can be used to assess general impact (baseline burden),
benefits, side effects, and impacts associated with oral
steroid use over time in patients with SLE.
Methods
Study population
Patients with a clinical diagnosis of SLE according to the
American College of Rheumatology classification criteria
[12] were recruited from six US rheumatology practices
(Mid-Atlantic: Arlington, VA; Titusville, NJ; South:
Gainesville, GA; Fort Lauderdale, FL; West Coast: Pacifica,
CA; and Midwest: Lansing, MI). Patients were screened
and selected with the aim of enrolling a diverse and repre-
sentative sample, including African Americans, patients
with a wide range of age, time since diagnosis and organ
involvement, and some patients in paid employment. All
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age. Potential participants were approached either at the
clinic or by telephone and invited to participate in the
study by the study site personnel. The study participants
contributed to the development of several PRO measures;
33 of the 41 patients comprising the full development
sample were currently receiving steroids or had re-
ceived steroids in the past year, and were therefore
included in the development of the SSQ. Develop-
ment of the other PRO measures will be reported
elsewhere [13]. All patients provided written, in-
formed consent upon enrollment in the study. Study
sites and participants were remunerated fair market
value for their participation.Development of the SSQ
Figure 1 summarizes the scientifically rigorous develop-
ment process used to develop the SSQ. The study proto-
col was developed and reviewed, then approved by an
independent review board, the Copernicus Group. All
sites received training on the conduct of the study and
were required to complete a clinical case report form for
each enrolled patient.Fig. 1 Development process of the SSQ. aNo patients took part in both the
elicitation; ePRO, electronic patient-reported outcome; FDA, Food and Drug
outcome; SSQ SLE Steroid QuestionnairePatients with SLE participated in face-to-face concept
elicitation (CE) interviews conducted by interviewers
trained in PRO development. Demographic information
was collected using a background questionnaire. Using a
semi-structured interview guide, patients were asked
open-ended questions about their steroid experience,
including duration of steroid use and the benefits, side
effects, and impacts of steroid use. While patients were
questioned on the side effects of steroids, safety of other
treatments was not formally assessed. Based on the
results of these interviews and input from clinicians, the
draft SSQ was developed.
To evaluate the content, clarity and relevance of the
draft SSQ, face-to-face cognitive debriefing (CD) semi-
structured interviews were conducted with a second
sample of patients with SLE, recruited from four of the
six US rheumatology practices. Prior to the face-to-face
CD interview, patients completed a draft paper version
of the SSQ formatted to look like screen shots, as the
questionnaire will ultimately be administered using an
electronic format (ePRO). In parallel with the CD inter-
views, a translatability assessment of the draft SSQ was
performed to ensure easy translation into three repre-
sentative languages: German, Japanese, and Portuguese.CE and CD interviews. CD, cognitive debriefing; CE, concept
Administration; IRB, independent review board; PRO, patient-reported






Mean age (SD), years 47.0 (11.13)
Age range, years 24–71
Ethnicity, % (n/N)
Caucasian 50 (16/32)








Mean SELENA-SLEDAI (SD) (n = 30) 6.8 (3.36)
Mean SLICC (SD) (n = 18) 5.8 (1.54)





Currently receiving steroids, % (n) 58 (19)
Average steroid dose of current users
(n = 18), mg/day
8.7 ± 5.35
(range: 4–20)
Mean (min, max) duration of steroid use
(n = 23), months
41.7 (0.2, 144)
Reasons for initiating steroid use, % (n/N)
To treat an SLE flare 26 (5/19)
To control swelling (hands or other body parts) 16 (3/19)
To treat joint pain and stiffness 16 (3/19)
To treat autoimmune thrombocytopenia/low
platelet count
16 (3/19)
CE concept elicitation, N number of patients with data available, NSAIDs non-
steroidal anti-inflammatory drugs, SD standard deviation, SELENA-SLEDAI Safety
of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus
Erythematosus Disease Activity Index, SLE systemic lupus erythematosus, SLICC
systemic lupus international collaborating clinics
aPatients who answered questions regarding their steroid experience; where n
does not equal 33, data were missing
b13 patients were receiving more than one treatment
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results, clinician input, and the translatability assessment
results.
Data analysis
All interviews were recorded and transcribed for analysis
purposes. All data were held in accordance with local,
state, and federal laws regarding confidentiality. Patient
identifiable information was not included in any interview
recordings, transcripts nor analyses, to ensure patient
confidentiality.
Analyses were conducted using the full sample; how-
ever, due to the length of the interviews, not all ques-
tions in the CE and CD interviews were asked of all
patients.
Data were analyzed using the qualitative data analysis
software, MAXQDA (Verbi GmbH, Berlin, Germany).
Two separate coding dictionaries were developed for
analysis of the CE and CD interview transcripts. To
ensure consistency across coders, descriptions and
examples for each code were included. Each transcript
was coded by one coder and then reviewed, summarized,
and analyzed by a second coder.
Results
CE interviews
In June and July 2014, 41 patients with SLE completed
CE interviews. Of these, 33 patients had a clinical record
of steroid use in the previous year and completed inter-
view questions about their experiences with steroids.
The majority were female (97%), 50% were Caucasian,
and 31% were African American; 19 patients were
currently receiving steroids, with a mean (standard devi-
ation) dose of 8.7 (5.35) mg/day (n = 18). The majority
(82%) of patients were currently receiving concomitant
medication, of which hydroxychloroquine was the most
common (67%). Mean time since diagnosis was approxi-
mately 88 months (n = 17). Rheumatologists reported
that approximately half (n = 17) of patients had moder-
ate SLE and one patient had severe SLE. In the majority
of cases, patients reported that it was the decision of the
rheumatologist to initiate steroids (82%) and three pa-
tients (18%) stated that they made the decision jointly
with their rheumatologist. The most common reason for
initiating steroids was to treat an SLE flare (Table 1).
The concepts mentioned with high frequency during
the CE interviews are shown in Table 2. The most com-
monly reported side effects (≥10% of patients) were weight
gain (67%), swelling/moon face (36%), mood swings/feel-
ings of rage (21%), and difficulty sleeping (12%). Of
patients currently taking steroids, 53% reported that they
were not currently experiencing any side effects.
When asked how taking steroids made them feel (n = 19),
in general, patients reported symptom improvement andincreased energy. For example, one patient stated, “I just felt
like, you know like how you would feel on a really good day,
you know you had the best night’s sleep and everything is
going right, you’re having a great day and you have all the
energy you need, the sun is shining. That’s what it was like.”
However, the negative impacts of steroids were also
Table 2 Concepts discussed during CE interviews
% (n/N) of patients
(n = 33)a
Before receiving steroids
Potential side effects discussed 71 (12/17)
Had expectations of the side effects 59 (10/17)
Perceived advantages of taking steroids
It would be effective 31 (5/16)
Would have more energy 25 (4/16)
Would have less joint pain 25 (4/16)
Perceived disadvantages of taking steroids
Weight gain 56 (9/16)
Potential long-term side effects eg,
kidney problems and bone loss
38 (6/16)
After receiving steroids: side effects
Expectations about side effects did not
match experienceb
50 (8/16)
Most commonly reported side effects
(reported by ≥10% of patients)
Weight gain 67 (22/33)
Swelling/moon face 36 (12/33)
Mood swings/feelings of rage 21 (7/33)
Difficulty sleeping 12 (4/33)
Most bothersome side effects
Weight gain 64 (14/22)
Sleeplessness 14 (3/22)
After receiving steroids: dosage
Have received a higher dose than they
typically/currently take
85 (22/26)
Have received a lower dose than they
typically/currently take
38 (10/26)
Stopped or changed dose without
consulting physician
30 (8/27)
Satisfaction with steroid treatment
Overall satisfied with steroids 75 (12/16)
Would be happy if treatment regimen did
not include steroids
67 (12/18)
CE concept elicitation, N number of patients asked
aPatients who answered questions regarding their steroid experience; where n
does not equal 33, data were missing/concepts were not discussed
bMost patients reported side effects were worse than expected
Mathias et al. Health and Quality of Life Outcomes  (2017) 15:43 Page 5 of 9described, for example, “The prednisone really helped the
symptoms, but it made me feel sicker. Like you know the
flares went away, but then I was overweight and
bloated and you know my joints were swollen from
the water. So I felt sicker even though I wasn’t having
like you know massive flares.”
When asked to put into one sentence their feelings
about steroids (n = 16), many patients reported mixed
feelings; steroids improved their SLE symptoms, but at
the cost of experiencing side effects. For example,patients responded, “I think they’re a two-edged sword
because on one hand they help you and on the other
hand they hurt you” and “I have a love/hate relationship
with them.” Overall, 75% of patients were satisfied with
steroid treatment, while 67% of patients would be happy
if they no longer needed to take steroids.
Development of the SSQ
Based on analysis of the CE transcripts, a draft version
of the SSQ was developed. Two rheumatologists then
made minor revisions to the SSQ. For example, for
consistency, items about side effects and benefits were
revised to use the same response options. Additionally, a
new item was added to assess the highest dose of
steroids ever received and another item was added to
enquire about feeling nervous or anxious.
The resulting draft questionnaire contained 51
items, which assessed steroid dose and duration (4
items), impact of steroids in general (18 items), bene-
fits of steroids (8 items), work/productivity (3 items),
side effects (10 items), emotions (7 items), and overall
satisfaction (1 item).
CD interviews and questionnaire refinement
To assess the content and clarity of the draft question-
naire, 13 patients with mild to moderate SLE completed
CD interviews; 7/13 were currently treated with steroids
and the other 6/13 had taken steroids within the past
year. Interviews focused on questions that could have
been challenging. For example, the question, did you ex-
perience reduced or less muscle pain or achiness?’ was
debriefed, as it was thought that the term ‘achiness’ may
have been difficult to understand.
All patients asked (n = 12) were able to accurately para-
phrase the instructions on the SSQ and none (n = 10) had
any suggestions for revisions.
The first four items in the SSQ ask about steroid dose
and duration of treatment. Although all patients asked
(n = 9) felt that it was easy to remember their current
dose, 50% (5/10) of patients asked thought it was diffi-
cult to remember their highest dose.
Eighteen items ask patients about their general experi-
ence of steroids, including the benefits and side effects
of steroids and the impacts of steroids on their daily life
75% of patients reported that it was easy to think about
this. Fourteen items refer to specific benefits and side ef-
fects of taking steroids. When asked how easy or diffi-
cult it was to know if they were experiencing a side
effect or benefit due to taking steroids or something else,
70% (n = 7/10) thought it was easy for most questions.
Three patients thought that for more than one question
it was difficult to know if the side effect was due to ste-
roids; these included questions assessing energy level,
mood, memory, daily activities, leisure activities, and
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responded: “But, you know, when it comes to like my en-
ergy level I don’t know if that’s the steroids or the Lupus.
The memory, I don’t know if that’s really with the two of
them, or one of them, or…you know, some of them I don’t
really know if it’s the steroids, the Lupus, or another
medication that I might be on.” Of patients who reported
swelling or ‘moon face’, mood swings or feelings of rage,
and weight gain, the majority (≥75%) reported that these
occurred while on higher doses of steroids than while on
their current dose. Some patients with mild SLE felt that
some items were not relevant to them because they had
not experienced them. For example, two patients re-
ported having no difficulty sleeping and one patient re-
ported not experiencing an increased appetite, feeling
nervous/agitated, having a loss of memory, or being un-
able to concentrate.
When asked what time frame they considered when
answering the questions on side effects, 71% of pa-
tients (n = 5/7) thought about the past 7 days, while
29% (n = 2/7) thought about the time since they first
started taking steroids or in general. These results
supported using a 7-day recall period for questions
regarding steroid benefits and side effects in the sec-
ond draft of the questionnaire. This time frame was
also selected as it was considered to be short enough
for patients to accurately recall their experiences, but
long enough to ensure that a representative picture
would be captured.
Seven items covered the range of emotions experi-
enced in the last 7 days; most patients (n = 5/8) did not
think there were any missing items. One patient sug-
gested adding an item on feeling helpless or incapaci-
tated, one suggested an item about feeling anxious, and
one suggested an item about feeling stressed. As these
items were suggested by a small number of patients,
they were not added to the questionnaire.
Overall, respondent feedback was that the draft SSQ
was comprehensive, clear, and relevant.
Based on the CD interviews, minor modifications were
made to the SSQ to improve the clarity, including
adding examples of side effects to the questions regarding
short- and long-term side effects.
Minor changes were also made to the SSQ based on
the translatability assessment. For example, the wording
of the instructions “You may have been taking steroids
for a short period of time or on and off for many years”
was modified to “You may have been taking steroids for
a short period of time, a long period of time, or you may
have started and stopped steroids many times”, as the
term “on and off” is difficult to translate into Japanese
and German.
The refined SSQ contains 50 items; sample questions
are shown in Table 3. Questions regarding the generalimpact of steroids do not specify a recall period and
typically provide five response options, for example,
much better, somewhat better, the same, somewhat
worse, much worse. The majority of questions regarding
the benefits and side effects of steroids use an 11-point
numeric rating scale ranging from 0 (absent/did not
have) to 10 (worst imaginable).
Discussion
To our knowledge, this is the first comprehensive PRO
measure to assess patient experience with oral steroids
in SLE developed in accordance with the FDA PRO
Guidance [11]. Patient and clinician input were obtained
in all stages of the iterative development of the SSQ.
This is an important criterion, as it ensures PROs are
comprehensive and that they capture concepts that pa-
tients feel are most relevant.
The CE interviews captured the patients’ experi-
ence with steroid treatment and revealed the mixed
attitudes patients have towards steroids, as they re-
ported both positive and negative impacts of steroid
therapy. The results of these interviews, together
with input from rheumatologists, were used to
develop the draft SSQ. Subsequently, patient CD in-
terviews evaluated the clarity, comprehensiveness and
relevance, and a translatability assessment was car-
ried out in parallel. Minor modifications were made
to the SSQ based on CD interview results, clinician
input, and translatability results.
The refined SSQ includes 50 items that assess steroid
dose/duration (4 items), impact of steroids in general (19
items), benefits of steroids (7 items), work/productivity (3
items), side effects (10 items), emotions (6 items), and
overall satisfaction (1 item). Questions regarding the bene-
fits and side effects of steroids use a 7-day recall period,
which was determined through patient feedback and
supported by clinicians, and enables changes in responses
to be captured accurately. The sensitivity of the SSQ to
time-dependent fluctuations is particularly important in
SLE, a disease characterized by flares (periods of increased
symptoms) followed by periods of quiescent disease or
lower disease activity that might be accompanied by
variations in the steroid dose. At 50 items, the SSQ
may be viewed as being too lengthy for clinical use.
However, it is important to note that the first 19
items assessing general experience with steroids are
only asked once at baseline, with only the remaining
31 items asked on an ongoing basis.
The SSQ is the first tool designed to evaluate the
overall steroid experience in SLE. It captures both
general experiences (baseline burden), and the pa-
tient’s recent experience of steroids. Importantly, it
goes beyond assessing the negative impacts associated
with steroid therapy (side effects) by also investigating
Table 3 Concepts included in the refined SSQ and sample questions
Concept (total number of
items)
Sample questions and response options
Steroid dose/duration (4) What dose of steroids are you
currently taking for lupus?
______mg/day OR
______mg ________(insert frequency, such as every day) OR
_______ mg as needed OR
□ I am not sure of my current dose
General impact of steroids
(baseline burden; 19)
In general, since you began
taking steroids:
Do you feel that steroids have






How much of the time have you
worried about short-term
side effects of steroids (weight
gain, mood changes, etc.)?
a) None of the time
b) A little bit of the time
c) Some of the time
d) Most of the time
e) All of the time
Benefits of steroids (7) While taking steroids for lupus in
the past 7 days, to what degree




1 2 3 4 5 6 7 8 9 10
Worst
imaginable
Work/productivity (3) While taking steroids for lupus in
the past 7 days, to what degree
did you experience improved
productivity at work?
a) Not at all
b) A little
c) Somewhat
d) Quite a bit
e) Very much
Side effects (10) While taking steroids for lupus in
the past 7 days, to what degree





1 2 3 4 5 6 7 8 9 10
Worst
imaginable
Emotions (6) While taking steroids for lupus in
the past 7 days, how much of
the time did you feel aggressive?
a) None of the time
b) A little bit of the time
c) Some of the time
d) Most of the time
e) All of the time
While taking steroids for lupus in
the past 7 days, how much of
the time did you feel self-confident?
a) None of the time
b) A little bit of the time
c) Some of the time
d) Most of the time
e) All of the time
Overall satisfaction (1) Overall, how satisfied have you




c) Neither satisfied nor dissatisfied
d) Dissatisfied
e) Very dissatisfied
SSQ SLE Steroid Questionnaire
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symptoms. In some cases, patients reported that it was
difficult to distinguish side effects caused by steroids
from symptoms of the disease, or other treatment side
effects; this may limit the ability of the SSQ to accur-
ately attribute burden to steroid use. Longitudinal use
and analysis of individual changes to the SSQ over time
may help to better differentiate between the effects of
steroids themselves, and other factors.
In addition to assessing the benefits, side effects and
other patient impacts of steroids, it is important to take
into account the wider economic consequences ofsteroid therapy. The severe side effects of steroids can
generate an additional economic burden; for example, a
recent study estimated the annual cost of steroid-related
AEs (fracture, cataract, diabetes, peptic ulcer, stroke, myo-
cardial infarction, and non-Hodgkin’s lymphoma) to be
£165/year per steroid-treated patient (2007 GB pounds,
equivalent to $344 [inflated to 2009 US$]) [14, 15].
Reducing the dose of steroids reduces the incidence of
steroid-related AEs and therefore the economic burden of
the therapy [14].
The 33 patients who completed the SSQ CE interviews
had a wide range of steroid exposure (less than 1 month
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who use steroids acutely and those who use them chron-
ically. In addition, the sample captured the diversity of
patients with SLE as it included both Caucasian and Af-
rican American patients, as well as patients with a range
of disease severity. Of the 33 patients enrolled in the CE
interviews, only one was male. Although the incidence
of SLE is much lower among men than women, [16] the
inclusion of more men in the study population would
have been preferable. Patients participating in the CD in-
terviews were all of moderate or mild severity. Patients
with mild SLE felt that some items were not relevant to
them because they had not experienced the benefit or
side effect, thus, some items (eg, having difficulty sleep-
ing) of the SSQ may only be relevant to patients with
moderate or severe SLE. Another potential limitation of
this study was the length of the CD interviews. Not all
questions could be asked of all patients; only a small
number of patients reviewed each item, though
interviews focused on items that were more challenging
in terms of patient understanding. Further studies will be
required to fully evaluate the SSQ in terms of its validity,
reliability, sensitivity, and responsiveness to change over
time (including a preliminary determination of a re-
sponder definition) before it can be used with confidence
in clinical studies and real-world clinical practice. Trad-
itional psychometric testing and exploratory factor ana-
lysis, should be conducted in order that both item and
scale scores can be used in the analysis of SSQ data.
Once adequate measurement properties of the SSQ
are demonstrated, the SSQ may have many uses in both
clinical studies and clinical practice. The SSQ can be
utilized in both cross-sectional and longitudinal studies.
For example, within clinical studies the SSQ may assess
the impact of steroids on specific SLE symptoms and
impacts and to assess the steroid-sparing effect of a ther-
apy. In the clinical practice setting, the baseline data
provided by the SSQ could be used by physicians to
assess the current burden of steroids on a patient. The
SSQ will also help physicians better understand patients’
desires and concerns regarding steroid therapy, improve
the physicians’ understanding of the impact of steroids,
and help guide physician decisions regarding altering a
patient’s steroid therapy. Although the SSQ was devel-
oped for use by patients with SLE, with modification
and further validation, it could also be applicable to
other patient populations in which steroid use is
common, such as severe asthma or giant cell arteritis.
Conclusions
In summary, the SSQ is a unique PRO measure designed
to comprehensively assess the benefits, side effects, and
other impacts of steroid treatment for patients. Follow-
ing confirmation of its measurement properties, the SSQmay prove a useful tool in both clinical studies and clin-
ical practice, to assess benefits and burdens associated
with steroid use, and the steroid-sparing effect of therap-
ies in SLE, with the potential for adaptation and use in
other disease areas.
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